Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the stock. JMP Securities reissued a market outperform rating and set a $6.00 price objective on shares of Cellectis in a report on Friday, May 31st. Oppenheimer cut their price target on shares of Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research note on Wednesday, June 12th.

Cellectis Price Performance

CLLS stock opened at $2.30 on Wednesday. The business’s 50-day moving average is $2.28 and its two-hundred day moving average is $2.59. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63. The firm has a market capitalization of $127.83 million, a P/E ratio of -1.78 and a beta of 3.10. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) EPS for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The business had revenue of $6.50 million during the quarter. Analysts anticipate that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. increased its holdings in Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 424,533 shares of the biotechnology company’s stock after acquiring an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned approximately 0.76% of Cellectis worth $1,125,000 at the end of the most recent quarter. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.